Chronic Obstructive Pulmonary Disease (COPD) MedDRA version: 15.0 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
Conditions
Interventions
Product Name: Umeclidinium/Vilanterol
Product Code: GSK573719/GW642444
Pharmaceutical Form: Inhalation powder, pre-dispensed
INN or Proposed INN: Umeclidinium
Current Sponsor code: GSK573719
Concentra
Sponsors
GlaxoSmithKline Research & Development Limited
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Subjects eligible for enrolment in the study must meet all of the following criteria: 1. Type of Patient: Outpatient 2. Informed Consent: A signed and dated written informed consent prior to study participation 3. Age: Subjects 40 years of age or older at Visit 1 4. Gender: Male or female subjects. A female is eligible to enter and participate in the study if she is of: - Non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is post-menopausal or surgically sterile). Surgically sterile females are defined as those with a documented hysterectomy and/or bilateral oophorectomy or tubal ligation. Post-menopausal females are defined as being amenorrhoeic for greater than 1 year with an appropriate clinical profile, e.g. age appropriate, > 45 years, in the absence of hormone replacement therapy. However in questionable cases, post-menopause status may be confirmed by analysis of a blood sample with Follicle-stimulating Hormone (FSH) > 40MIU/ml and estradiol = 10 pack-years at Visit 1 [number of pack years = (number of cigarettes per day / 20) x number of years smoked (e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years]. Former smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1. 7. Severity of Disease: A pre- and post-salbutamol FEV1/FVC ratio of =65 years) yes F.1.3.1 Number of subjects for this age range 60
Exclusion criteria
Exclusion criteria: Subjects meeting any of the following criteria must not be enrolled in the study: 1. Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study 2. Asthma: A current diagnosis of asthma 3. Other Respiratory Disorders: Known alpha-1 antitrypsin deficiency, active lung infections (such as tuberculosis), and lung cancer are absolute exclusionary conditions. A subject,who, in the opinion of the investigator, has any other significant respiratory condition in addition to COPD should be excluded. Examples may include clinically significant bronchiectasis, pulmonary hypertension, sarcoidosis, or interstitial lung disease. Allergic rhinitis is not exclusionary. 4. Other Diseases/Abnormalities: Subjects with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled and/or a previous history of cancer in remission for < 5 years prior to Visit 1 (localized carcinoma of the skin that has been resected for cure is not exclusionary). Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the safety analysis if the disease/condition exacerbated during the study. 5. Contraindications: A history of allergy or hypersensitivity to any anticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein or magnesium stearate or a medical condition such as of narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that, in the opinion of the study physician contraindicates study participation or use of an inhaled anticholinergic. 6. Hospitalization: Hospitalization for COPD or pneumonia within 12 weeks prior to Visit 1. 7. Lung Resection: Subjects with lung volume reduction surgery within the 12 months prior to Visit 1. 8. 12-Lead ECG: An abnormal and significant ECG finding from the 12-lead ECG conducted at Visit 1, Investigators will be provided with ECG reviews conducted by a centralized independent cardiologist to assist in evaluation of subject eligibility. Specific ECG findings that preclude subject eligibility are listed in Appendix 2. The study investigator will determine the medical significance of any ECG abnormalities not listed in Appendix 2. 9. Screening Labs: Significantly abnormal finding from clinical chemistry or hematology tests at Visit 1 as determined by the study investigator. 10. Medication Prior to Spirometry: Unable to withhold salbutamol for the 4 hour period required prior to spirometry testing at each study visit and at each spirometry test performed at home. 11. Medications Prior to Screening: Use of the following medications according to the following defined time intervals prior to Visit 1 (see table in Section 4.3 of Protocol) 12. Oxygen: Use of long-term oxygen therapy (LTOT) described as oxygen therapy prescribed for greater than 12 hours a day. As-needed oxygen use (i.e., ?12 hours per day) is not exclusionary. 13. Nebulized Therapy: Regular use (prescribed for use every day, not for as-needed use) of short-acting bronchodilators (e.g., salbutamol, ipratropium bromide) via nebulized therapy 14. Pulmonary Rehabilitation Program: Participation in the acute phase of a pulmonary rehabilitation program within 4 w
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The primary objective of this study is to evaluate the lung function response following treatment with UMEC 125mcg, VI 25mcg, and UMEC/VI 125/25mcg administered once-daily via the Novel Dry Powder Inhaler (NDPI) in subjects with COPD.;Secondary Objective: ;Primary end point(s): The primary efficacy endpoint is the weighted mean FEV1 over 0-6 hours post-dose on Day 14 of each treatment period.;Timepoint(s) of evaluation of this end point: 0-6 hours post-dose on Day 14 of each treatment period | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): • Proportion of subjects who were responsive to UMEC/VI, UMEC or VI according to FEV1 at Day 1 (responsive defined as an increase from baseline of at least 12% and 200mL at any time over 0-6 h post-dose) • Proportion of subjects who had a larger change from baseline in 0-6 h WM FEV1 on Day 14 with UMEC/VI compared with UMEC and VI alone • Trough FEV1 on Day 15 ;Timepoint(s) of evaluation of this end point: 0-6 hours post dose n Day 14 for Proportion of Subjects endpoints. Day 15 for Trough FEV1 | — |
Countries
Estonia, Germany
Contacts
Public ContactGSK Clinical Support HelpDesk
GlaxoSmithKline Research & Development Limited
Outcome results
None listed